Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal

Ramesh Kandimalla, Vani Thirumala, P (Hemachandra) Reddy

Research output: Contribution to journalReview article

93 Citations (Scopus)

Abstract

Recently researchers proposed the term ‘Type-3-Diabetes’ for Alzheimer's disease (ad) because of the shared molecular and cellular features among Type-1-Diabetes, Type-2-Diabetes and insulin resistance associated with memory deficits and cognitive decline in elderly individuals. Recent clinical and basic studies on patients with diabetes and AD revealed previously unreported cellular and pathological among diabetes, insulin resistance and AD. These studies are also strengthened by various basic biological studies that decipher the effects of insulin in the pathology of AD through cellular and molecular mechanisms. For instance, insulin is involved in the activation of glycogen synthase kinase 3β, which in turn causes phosphorylation of tau, which involved in the formation of neurofibrillary tangles. Interestingly, insulin also plays a crucial role in the formation amyloid plaques. In this review, we discussed significant shared mechanisms between AD and diabetes and we also provided therapeutic avenues for diabetes and AD. This article is part of a Special Issue entitled: Oxidative Stress and Mitochondrial Quality in Diabetes/Obesity and Critical Illness Spectrum of Diseases - edited by P. Hemachandra Reddy.

Original languageEnglish (US)
Pages (from-to)1078-1089
Number of pages12
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1863
Issue number5
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

Alzheimer Disease
Insulin
Insulin Resistance
Glycogen Synthase Kinase 3
Neurofibrillary Tangles
Amyloid Plaques
Memory Disorders
Type 1 Diabetes Mellitus
Critical Illness
Type 2 Diabetes Mellitus
Oxidative Stress
Obesity
Phosphorylation
Research Personnel
Pathology
Therapeutics
Alzheimer disease, familial, type 3
Clinical Studies
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • BMI
  • diabetes
  • GSK3β
  • MCI amyloid beta
  • Obesity
  • Tau
  • Type-3-Diabetes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. / Kandimalla, Ramesh; Thirumala, Vani; Reddy, P (Hemachandra).

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1863, No. 5, 01.05.2017, p. 1078-1089.

Research output: Contribution to journalReview article

Kandimalla, Ramesh ; Thirumala, Vani ; Reddy, P (Hemachandra). / Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2017 ; Vol. 1863, No. 5. pp. 1078-1089.
@article{55c344860dd24dd08f66b9c8f57b9b9e,
title = "Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal",
abstract = "Recently researchers proposed the term ‘Type-3-Diabetes’ for Alzheimer's disease (ad) because of the shared molecular and cellular features among Type-1-Diabetes, Type-2-Diabetes and insulin resistance associated with memory deficits and cognitive decline in elderly individuals. Recent clinical and basic studies on patients with diabetes and AD revealed previously unreported cellular and pathological among diabetes, insulin resistance and AD. These studies are also strengthened by various basic biological studies that decipher the effects of insulin in the pathology of AD through cellular and molecular mechanisms. For instance, insulin is involved in the activation of glycogen synthase kinase 3β, which in turn causes phosphorylation of tau, which involved in the formation of neurofibrillary tangles. Interestingly, insulin also plays a crucial role in the formation amyloid plaques. In this review, we discussed significant shared mechanisms between AD and diabetes and we also provided therapeutic avenues for diabetes and AD. This article is part of a Special Issue entitled: Oxidative Stress and Mitochondrial Quality in Diabetes/Obesity and Critical Illness Spectrum of Diseases - edited by P. Hemachandra Reddy.",
keywords = "Alzheimer's disease, BMI, diabetes, GSK3β, MCI amyloid beta, Obesity, Tau, Type-3-Diabetes",
author = "Ramesh Kandimalla and Vani Thirumala and Reddy, {P (Hemachandra)}",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.bbadis.2016.08.018",
language = "English (US)",
volume = "1863",
pages = "1078--1089",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal

AU - Kandimalla, Ramesh

AU - Thirumala, Vani

AU - Reddy, P (Hemachandra)

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Recently researchers proposed the term ‘Type-3-Diabetes’ for Alzheimer's disease (ad) because of the shared molecular and cellular features among Type-1-Diabetes, Type-2-Diabetes and insulin resistance associated with memory deficits and cognitive decline in elderly individuals. Recent clinical and basic studies on patients with diabetes and AD revealed previously unreported cellular and pathological among diabetes, insulin resistance and AD. These studies are also strengthened by various basic biological studies that decipher the effects of insulin in the pathology of AD through cellular and molecular mechanisms. For instance, insulin is involved in the activation of glycogen synthase kinase 3β, which in turn causes phosphorylation of tau, which involved in the formation of neurofibrillary tangles. Interestingly, insulin also plays a crucial role in the formation amyloid plaques. In this review, we discussed significant shared mechanisms between AD and diabetes and we also provided therapeutic avenues for diabetes and AD. This article is part of a Special Issue entitled: Oxidative Stress and Mitochondrial Quality in Diabetes/Obesity and Critical Illness Spectrum of Diseases - edited by P. Hemachandra Reddy.

AB - Recently researchers proposed the term ‘Type-3-Diabetes’ for Alzheimer's disease (ad) because of the shared molecular and cellular features among Type-1-Diabetes, Type-2-Diabetes and insulin resistance associated with memory deficits and cognitive decline in elderly individuals. Recent clinical and basic studies on patients with diabetes and AD revealed previously unreported cellular and pathological among diabetes, insulin resistance and AD. These studies are also strengthened by various basic biological studies that decipher the effects of insulin in the pathology of AD through cellular and molecular mechanisms. For instance, insulin is involved in the activation of glycogen synthase kinase 3β, which in turn causes phosphorylation of tau, which involved in the formation of neurofibrillary tangles. Interestingly, insulin also plays a crucial role in the formation amyloid plaques. In this review, we discussed significant shared mechanisms between AD and diabetes and we also provided therapeutic avenues for diabetes and AD. This article is part of a Special Issue entitled: Oxidative Stress and Mitochondrial Quality in Diabetes/Obesity and Critical Illness Spectrum of Diseases - edited by P. Hemachandra Reddy.

KW - Alzheimer's disease

KW - BMI

KW - diabetes

KW - GSK3β

KW - MCI amyloid beta

KW - Obesity

KW - Tau

KW - Type-3-Diabetes

UR - http://www.scopus.com/inward/record.url?scp=85019158021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019158021&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2016.08.018

DO - 10.1016/j.bbadis.2016.08.018

M3 - Review article

C2 - 27567931

AN - SCOPUS:85019158021

VL - 1863

SP - 1078

EP - 1089

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 5

ER -